KRAS and non-small cell lung carcinoma: Initial inhuman data from the phase I CodeBreaK 100 (NCT03600883) trial of sotorasib provided evidence for its single-agent activity and efficacy in patients with heavily pretreated (ICIs and platinum-based chemotherapy) advanced solid tumors with KRAS G12C mutations, including a partial response (PR) in one of six patients with advanced NSCLC.82,91,221 The trial included a total of 129 patients (59 with NSCLS, 42 with CRC, and 28 with other tumors).